Clinical care is provided by Arora Health & Aesthetics, and medication is prepared by US-based state-licensed 503A compounding pharmacy partners. Somira Health itself is not a medical provider.
The FDA resolved the semaglutide shortage on April 22, 2025. Compounding is permitted only for individually identified patients when a prescribing practitioner determines that the compounded preparation produces a significant difference for their patient compared to the FDA-approved product.
Cancellation and Refund
Subscriptions auto-renew and can be paused or cancelled at any time in the patient portal, with no commitment.